Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 3, March, p. 401–407

doi: 10.17219/acem/68545

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Severe infections caused by multidrug-resistant non-fermentative bacilli in southern Poland

Agnieszka Chmielarczyk1,A,B,C,D,F, Monika Pobiega1,B,C, Grzegorz Ziółkowski2,B, Monika Pomorska-Wesołowska3,B, Dorota Romaniszyn1,C, Lech Krawczyk2,E, Jadwiga Wójkowska-Mach1,A,E,F

1 Chair of Microbiology, Jagiellonian University Medical College, Kraków, Poland

2 Higher School of Medicine in Sosnowiec, Poland

3 Department of Microbiology, Analytical and Microbiological Laboratory, KORLAB Non-public Healthcare Center, Ruda Śląska, Poland


Background. The impact of multidrug-resistant organisms (MDROs), including non-fermentative bacilli (NFBs), is rising and underestimated, especially in intensive care units (ICUs). The growing prevalence of multidrug resistance (MDR) and extensive drug resistance (XDR) is challenging for clinicians, as the treatment options are limited.
Objectives. The purpose of this study was to analyze the extent of the epidemiological problem of multidrugresistant, extensively drug-resistant and pandrug-resistant (PDR) non-fermentative bacilli isolated from pneumonia and bloodstream infections (BSIs) in patients hospitalized in southern Poland.
Material and Methods. This study included 253 NFBs belonging to Acinetobacter sp. (ACI), Pseudomonas sp. (PAR), and Stenotrophomonas sp. (STM). The microorganisms were identified, and susceptibility testing was performed using a semi-automatic system. The different patterns of resistance were defined as MDR, XDR, or PDR strains. Epidemiological typing of A. baumannii from ICUs was performed by repetitive polymerase chain reaction (rep-PCR).
Results. More than half of the strains (57.7%) were isolated within ICUs. ACI-strains came significantly more often from ICU wards. The highest prevalence of ACI and PAR was found in pneumonia, whereas STM dominated in BSIs. ACIs were more frequently resistant than other pathogens to all studied antibiotics except colistin (n = 76; 58.9%), and they belonged to the XDR category. DiversiLab demonstrated the presence of 2 dominant clones in the ACI group, both classified as European Clone 2 (EUII).
Conclusion. Our results indicate serious potential therapeutic problems related to high antibiotic resistance of ACI isolates. The stratification of drug resistance (MDR/XDR/PDR) may become an important tool for the assessment of public health epidemiology and microbiological hazards at the local, national, and international level. It allows clear presentation of the issues concerning the epidemiology of highly resistant bacilli, and the exchange of information between medical staff and local representatives of public health for the implementation of effective measures to reduce drug resistance.

Key words

pneumonia, multidrug resistance, non-fermentative bacilli, bloodstream infections

References (25)

  1. Martín-Loeches I, Diaz E, Vallés J. Risks for multidrug-resistant patho- gens in the ICU. Curr Opin Crit Care. 2014;20(5):516–524.
  2. Rossolini GM. Acquired metallo-beta-lactamases: An increasing clin- ical threat. Clin Infect Dis. 20051;41(11):1557–1558.
  3. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: Epidemiol- ogy and treatment options. Pharmacotherapy. 2005;25:1353–1364.
  4. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of car- bapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. Erratum in: J Antimicrob Chemother. 2010;65(6):1317.
  5. Rossolini GM, Mantengoli E. Treatment and control of severe infec- tions caused by multiresistant Pseudomonas aeruginosa. Clin Micro- biol Infect. 2005;11(4):17–32.
  6. Qureshi ZA, Hittle LE, O’Hara JA, et al. Colistin-resistant Acineto- bacter baumannii: Beyond carbapenem resistance. Clin Infect Dis.
  7. O’Hara JA, Ambe LA, Casella LG, et al. Activities of vancomycin-con- taining regimens against colistin-resistant Acinetobacter bauman- nii clinical strains. Antimicrob Agents Chemother. 2013;57(5):2103–
  8. Vallés J, Martin-Loeches I, Torres A, et al. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumo- nia in critically ill patients: A Spanish cohort study. Intensive Care Med. 2014;40(4):572–581.
  9. European Centre for Disease Prevention and Control – An agen- cy of the European Union. Publications/healthcare-associated-infections-HAI-ICU-protocol. pdf Accessed August 2016.
  10. EUCAST: Clinical breakpoints. points/ Accessed September 25, 2015.
  11. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug resistant, extensively drug-resistant and pan-drug-resistant bacteria: An inter- national expert proposal for interim standard definitions for acquired resistance. Clin Microbial Infect. 2012;18:268–281.
  12. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471–384.
  13. Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: Evolution of a global pathogen. Pathog Dis. 2014;71(3):292–301.
  14. Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, anti- microbial resistance, and treatment options. Clin Infect Dis. 2008;15;46(8):1254–1263. doi: 10.1086/529198
  15. Annual Epidemiological Report 2014. Antimicrobial resistance and healthcare-associated infections. topics/antimicrobial_resistance/database/Pages/database.aspx. Accessed August, 2015.
  16. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Anti- microb Agents Chemother. 2004;48(12):4606–4610.
  17. Sacha P, Michalska A, Ojdana D, et al. Identification of plasmid OXA and other β-lactamase genes among carbapenem-resistant isolates of Pseudomonas aeruginosa from the Clinical University Hospital in north-eastern Poland. New Microbiol. 2015;38(2):271–275.
  18. Pobiega M, Wojkowska-Mach J, Maciag J, et al. Virulence and antibiotic resistance of Pseudomonas aeruginosa isolated from patients with urinary tract infections in southern Poland. Chemotherapy. 2014; 60(4):253–260.
  19. Brooke JS. New strategies against Stenotrophomonas maltophilia: A serious worldwide intrinsically drug-resistant opportunistic patho- gen. Expert Rev Anti Infect Ther. 2014;12(1):1–4.
  20. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospi- talised patients with pneumonia in US and European medical cen- tres (2012). Int J Antimicrob Agents. 2014; 43(6):533–539.
  21. Meyer E, Schwab F, Gastmeier P, Rüden H, Daschner FD. Is the prev- alence of Stenotrophomonas maltophilia isolation and nosocomial infection increasing in intensive care units? Eur J Clin Microbiol Infect Dis. 2006;25:711–714.
  22. Wang CH, Lin JC, Lin HA, et al. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sul- famethoxazole-resistant Stenotrophomonas maltophilia monomi- crobial bacteremia: A 10-year retrospective study. J Microbiol Immu- nol Infect. 2014;49(3):378–386.
  23. Chung HS, Hong SG, Kim YR, et al. Antimicrobial susceptibility of Ste- notrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci. 2013;28(1):62–66.
  24. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R; BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-neg- ative bacteria from bacteraemias in the UK and Ireland, 2001–06. J Antimicrob Chemother. 2008;62(2):ii55–63.
  25. Hankiewicz-Ziołkowska K, Mikucka A, Gospodarek E. Clinical strains isolation and antibiotic susceptibility of Stenotrophomonas malto- philia. Med Dosw Mikrobiol. 2010;62(2):127–134.